FeesSafety
Pluang+

VolitionRx partners with Missionpharma to develop a rapid test for neonatal sepsis using lateral flow technology.

Market News
27 Oct 2026, 15:47 WIB
PRNewsWire
View Source
Bullish
VolitionRx partners with Missionpharma to develop a rapid test for neonatal sepsis using lateral flow technology.

VolitionRx has signed a non-binding Letter of Intent with Missionpharma to develop and launch a lateral flow test (LFT) prototype for detecting NETosis, a key marker in sepsis. This finger-prick test aims to enable early diagnosis of neonatal sepsis, particularly in low- and middle-income countries, where sepsis is a leading cause of newborn deaths. The collaboration seeks to accelerate commercialization and improve access to this potentially life-saving diagnostic tool in resource-limited and humanitarian settings. The initial focus will be on validating the test's use for triaging and prognosis in newborns and young infants with sepsis.

VolitionRx's new collaboration with Missionpharma for a lateral flow test is presented here with Pluang's health sector market data as context. As of Oct 27, 2026 18:51 WIB, 77 of 150 priced health-sector US stocks rose while 66 fell. BioNano Genomics Inc (BNGO) traded at USD 1.18 with a 1-day change of +1.72% and a typical hold time of 51 days on Pluang.

More News

CareCloud appoints Mitchell Brie as Chief Compliance Officer to boost its healthcare compliance services.

CareCloud appoints Mitchell Brie as Chief Compliance Officer to boost its healthcare compliance services.

CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...

Market News
Bullish
1 hour ago
Defense contractors must review CUI access before licensing Microsoft 365 Copilot in GCC High cloud.

Defense contractors must review CUI access before licensing Microsoft 365 Copilot in GCC High cloud.

eSoftware Associates advises defense contractors to carefully map controlled unclassified information (CUI) access permissions before licensing Microsoft 365 Copilot in the GCC High cloud environment. Moving to GCC High does not automatically grant c...

Market News
Neutral
2 hours ago
Man Group discloses 5.64% stake in Vesuvius plc amid offer involving RHI Magnestia N.V.

Man Group discloses 5.64% stake in Vesuvius plc amid offer involving RHI Magnestia N.V.

Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...

Neutral
2 hours ago
Nautilus reports Q3 2026 results with $0.2M revenue, $15.6M net loss, and advances in proteome analysis tech.

Nautilus reports Q3 2026 results with $0.2M revenue, $15.6M net loss, and advances in proteome analysis tech.

Nautilus Biotechnology announced its Q3 2026 financial results, reporting $0.2 million in revenue mainly from grants and early access services, and a net loss of $15.6 million. The company highlighted progress in its proteome analysis platform, inclu...

Company Fundamentals
Bullish
3 hours ago
Eviden launches ASTRA-LAS, a new AI-powered tactical decision-support tool for naval operations.

Eviden launches ASTRA-LAS, a new AI-powered tactical decision-support tool for naval operations.

Eviden, part of Atos Group, has introduced ASTRA-LAS, a tactical decision-support solution designed to aid naval officers in complex maritime environments. The system uses operational data and AI to enhance situational awareness, reduce cognitive loa...

Others
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App